Drug Profile
Relmapirazin - MediBeacon
Alternative Names: APC2; Lumitrace; MB 102; MP-3180; PP 2338Latest Information Update: 09 Jan 2024
Price :
$50
*
At a glance
- Originator Mallinckrodt Inc.
- Developer MediBeacon
- Class Diagnostic agents; Pyrazines; Small molecules
- Mechanism of Action Diagnostic imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Acute kidney injury; Kidney disorders
- No development reported Crohn's disease
Most Recent Events
- 30 Nov 2023 Hangzhou Zhongmei Huadong Pharmaceutical completes a phase III trial in Kidney disorders (Diagnosis) in China (IV) (NCT05943977)
- 30 Nov 2023 MediBeacon reinitiates a phase III trial in Acute kidney injury and Kidney disorders (Diagnosis) in USA (IV) (NCT05777174)
- 31 Aug 2023 MediBeacon suspends a phase III trial in Acute kidney injury and Kidney disorders (Diagnosis) in USA (IV) to submit an IDE amendment (NCT05777174)